Problem or Solution: The Strange Story of Glucagon

Overview

Journal Peptides

Specialty Biochemistry

Date 2018 Feb 8

PMID 29412829

Citations 21

Authors

R V Scott

S R Bloom

Affiliations

Soon will be listed here.

Abstract

Globally, 13% of the world's adult population is obese, and more than 400 million people suffer from diabetes. These conditions are both associated with significant morbidity, mortality and financial cost. Therefore, finding new pharmacological treatments is an imperative. Relative hyperglucagonaemia is seen in all types of diabetes, and has been implicated in its pathogenesis. Consequently, clinical trials are underway using drugs which block glucagon activity to treat type 2 diabetes. Conversely, exogenous glucagon can increase energy expenditure. Therefore, researchers are designing peptides that combine activation of the glucagon receptor with further incretin properties, which will treat obesity while mitigating the hyperglycaemic effects of glucagon. This review will discuss these conflicting physiological properties of glucagon, and the attempts to harness these effects pharmacologically.

Citing Articles

A tumor-secreted protein utilizes glucagon release to cause host wasting.

Ding G, Li Y, Cheng C, Tan K, Deng Y, Pang H Cell Discov. 2025; 11(1):11.

PMID: 39924534 PMC: 11808122. DOI: 10.1038/s41421-024-00762-0.

Comparative Effect of Insulin Resistance Reduction and Hormonal Alterations on Type 2 Diabetes Remission After Bariatric Surgery.

Shestakova E, Stafeev I, Yashkov Y, Yurasov A, Tomilova A, Parfyonova Y J Clin Med. 2024; 13(22).

PMID: 39598143 PMC: 11595085. DOI: 10.3390/jcm13226998.

Larval density can be used to predict genetic modifiers of glucagon signaling in Drosophila melanogaster.

Nicol A, Ahmed M, Fischer C, Garces J, Magnus S, Maung N PLoS One. 2024; 19(8):e0302565.

PMID: 39196987 PMC: 11356449. DOI: 10.1371/journal.pone.0302565.

Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes.

Zhu J, Wilding J Curr Atheroscler Rep. 2023; 26(1):1-10.

PMID: 38148417 PMC: 10776473. DOI: 10.1007/s11883-023-01181-4.

Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.

Bays H, Fitch A, Christensen S, Burridge K, Tondt J Obes Pillars. 2023; 2:100018.

PMID: 37990711 PMC: 10662004. DOI: 10.1016/j.obpill.2022.100018.

References

Finan B, Clemmensen C, Zhu Z, Stemmer K, Gauthier K, Muller L . Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease. Cell. 2016; 167(3):843-857.e14. DOI: 10.1016/j.cell.2016.09.014. View

Holst J, Holland W, Gromada J, Lee Y, Unger R, Yan H . Insulin and Glucagon: Partners for Life. Endocrinology. 2017; 158(4):696-701. PMC: 6061217. DOI: 10.1210/en.2016-1748. View

Salem V, Izzi-Engbeaya C, Coello C, Thomas D, Chambers E, Comninos A . Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. Diabetes Obes Metab. 2015; 18(1):72-81. PMC: 4710848. DOI: 10.1111/dom.12585. View

Gerich J, Lorenzi M, Schneider V, Kwan C, KARAM J, Guillemin R . Inhibition of pancreatic glucagon responses to arginine by somatostatin in normal man and in insulin-dependent diabetics. Diabetes. 1974; 23(11):876-80. DOI: 10.2337/diab.23.11.876. View

Zhu W, Czyzyk D, Paranjape S, Zhou L, Horblitt A, Szabo G . Glucose prevents the fall in ventromedial hypothalamic GABA that is required for full activation of glucose counterregulatory responses during hypoglycemia. Am J Physiol Endocrinol Metab. 2010; 298(5):E971-7. PMC: 2867375. DOI: 10.1152/ajpendo.00749.2009. View

Dakin C, Small C, Batterham R, Neary N, Cohen M, Patterson M . Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology. 2004; 145(6):2687-95. DOI: 10.1210/en.2003-1338. View

van Can J, Sloth B, Jensen C, Flint A, Blaak E, Saris W . Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2013; 38(6):784-93. PMC: 4052428. DOI: 10.1038/ijo.2013.162. View

Muller W, Faloona G, Unger R . The effect of experimental insulin deficiency on glucagon secretion. J Clin Invest. 1971; 50(9):1992-9. PMC: 292125. DOI: 10.1172/JCI106691. View

Heim T, Hull D . The effect of propranalol on the calorigenic response in brown adipose tissue of new-born rabbits to catecholamines, glucagon, corticotrophin and cold exposure. J Physiol. 1966; 187(2):271-83. PMC: 1395936. DOI: 10.1113/jphysiol.1966.sp008088. View

10.

Hansen L, Abrahamsen N, Nishimura E . Glucagon receptor mRNA distribution in rat tissues. Peptides. 1995; 16(6):1163-6. DOI: 10.1016/0196-9781(95)00078-x. View

11.

VILLEE C . The effect of insulin on the incorporation of C14-labeled pyruvate and acetate into lipid and protein. Anat Rec. 1948; 101(4):680. View

12.

Kostic A, King T, Yang F, Chan K, Yancopoulos G, Gromada J . A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers. Diabetes Obes Metab. 2017; 20(2):283-291. PMC: 5813272. DOI: 10.1111/dom.13075. View

13.

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M . A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015; 373(1):11-22. DOI: 10.1056/NEJMoa1411892. View

14.

Yamato E, Noma Y, Tahara Y, Ikegami H, Yamamoto Y, Cha T . Suppression of synthesis and release of glucagon by glucagon-like peptide-1 (7-36 amide) without affect on mRNA level in isolated rat islets. Biochem Biophys Res Commun. 1990; 167(2):431-7. DOI: 10.1016/0006-291x(90)92041-w. View

15.

van Dongen M, Geerts B, Morgan E, Brandt T, de Kam M, Romijn J . First proof of pharmacology in humans of a novel glucagon receptor antisense drug. J Clin Pharmacol. 2014; 55(3):298-306. DOI: 10.1002/jcph.396. View

16.

Buchanan K, McCarroll A . Abnormalities of glucagon metabolism in untreated diabetes mellitus. Lancet. 1972; 2(7792):1394-5. DOI: 10.1016/s0140-6736(72)92964-9. View

17.

Jall S, Sachs S, Clemmensen C, Finan B, Neff F, DiMarchi R . Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. Mol Metab. 2017; 6(5):440-446. PMC: 5404097. DOI: 10.1016/j.molmet.2017.02.002. View

18.

Flakoll P, Borel M, Wentzel L, Williams P, Lacy D, Abumrad N . The role of glucagon in the control of protein and amino acid metabolism in vivo. Metabolism. 1994; 43(12):1509-16. DOI: 10.1016/0026-0495(94)90009-4. View

19.

TEWS J, Colosi N, Harpter A . Amino acid transport and turnover of a transport system in liver slices from rats treated with glucagon and antibiotics. Life Sci. 1975; 16(5):439-49. DOI: 10.1016/0024-3205(75)90350-1. View

20.

Neumann U, Ho J, Mojibian M, Covey S, Charron M, Kieffer T . Glucagon receptor gene deletion in insulin knockout mice modestly reduces blood glucose and ketones but does not promote survival. Mol Metab. 2016; 5(8):731-736. PMC: 5021664. DOI: 10.1016/j.molmet.2016.05.014. View